ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

LAT1 targeted brain delivery of temozolomide and sorafenib for effective glioma therapy

Zhang, Yufei; Cheng, Qian; Xue, Yuhao; Yao, Kai; Syeda, Madiha Zahra; Xu, Jian; Wu, Jianheng; Wang, Zhenjie*; Tang, Longguang*; Mu, Qingchun*广东医学院; 哈尔滨医科大学; 河北医科大学; 浙江大学; 1
Nano Research2023-7DOI: 10.1007/s12274-023-5568-3
2被引6阅读
引用收藏
分享

摘要

Glioma is the most common primary craniocerebral tumor caused by the cancerous growth of glial cells in the brain and spinal cord. Currently, standard treatment is the surgical resection followed by concurrent radiation and chemotherapy. However, the blood-brain barrier (BBB) prevents most antitumor drugs from entering the brain and reduces their efficacy, especially in low-grade glioma. Since L-type amino acid transporter 1 (LAT1) is highly expressed in glioma cells and mediates drug transport across the BBB, it is a promising target for drug delivery and treatment of glioma. Temozolomide (TMZ) is the first-line treatment for glioma, however, patients often exhibit drug resistance at advanced stage. A multikinase inhibitor and inducer of ferroptosis, sorafenib can improve the therapeutic effects of TMZ. Therefore, to optimize the glioma treatment and cross the BBB, we designed LAT1-targeting nanoparticles co-loaded with TMZ and sorafenib. Our results from both in vitro and in vivo studies confirmed that LAT1-targeting nanoparticles significantly increased the cellular uptake, cytotoxicity, accumulation at tumor site, and the anti-tumor efficacy compared to the non-target nanoparticles. Therefore, LAT1 can be used as a potential target for brain-targeted drug delivery, and sorafenib-induced ferroptosis can aid the anti-glioma efficacy of TMZ.

学科与关键词

关键词
L-type amino acid transporter 1 (LAT1)gliomablood-brain barrier (BBB)ferroptosisdrug delivery
相关
加载中…
  • Enhanced Efficacy of Temozolomide Loaded by Tetrahedral Framework DNA Nanoparticle in Therapy for Glioblastoma.
    Fu Wei; You Chao; Ma Lu; Li Hao; Ju Yan; Guo Xi; Shi Sirong; Zhang Tao; Zhou Ronghui; Lin Yunfeng2019.
  • Construction of IL-13 Receptor α2-Targeting Resveratrol Nanoparticles against Glioblastoma Cells: Therapeutic Efficacy and Molecular Effects
    Lin, Xiao-Min; Shi, Xiao-Xiao; Xiong, Le; Nie, Jun-Hua; Ye, Hai-Shan; Du, Jin-Zi; Liu, Jia*INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22(19): 10622.被引 6
  • Polyhedral Oligomeric Silsesquioxane-Based Nanoparticles for Efficient Chemotherapy of Glioblastoma
    Zhong, Xiangyang; Wei, Gang; Liu, Boyang; Wang, Chenyang; Wang, Juan; Lu, Yong*; Cui, Wenguo*; Guo, Hongbo*Small, 2023, 19(18).被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Nano Research
发表日期
2023-07
卷期
第 16 卷, 第 7 期
页码
9743-9751
DOI
10.1007/s12274-023-5568-3
语言
ENGLISH
期刊收录
CAST-L
成果收录
SCIE
资助标注
National High Technology Research and Development Program of China [2019YFC0121000]; National Natural Science Foundation of China [32201127, 82270113]; Medical Scientific Research Foundation of Guangdong Province, China [A2021298]

作者

  • Z

    Zhang, Yufei (第一作者)

    guilin med univ

  • C

    Cheng, Qian

    guilin med univ

查看全部 10 位作者收起作者
  • X

    Xue, Yuhao

    mudanjiang med univ

  • Y

    Yao, Kai

    1 · harbin med univ

  • S

    Syeda, Madiha Zahra

    guangdong med univ

  • X

    Xu, Jian

    inst med · zhejiang univ

  • W

    Wu, Jianheng

    guangdong med univ

  • W

    Wang, Zhenjie (通讯)

    guangdong med univ

  • T

    Tang, Longguang (通讯)

    inst med · zhejiang univ

  • M

    Mu, Qingchun (通讯)

    guangdong med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417